Amphastar Pharmaceuticals
| Company type | Public |
|---|---|
| Headquarters | Rancho Cucamonga, California, United States |
Key people |
|
| Revenue |  US$ 240.18 million (2017) |
 US$ -895 thousand (2017) | |
| US$ -4.51 million (2017) | |
| Total assets | US$ 454.67 million (2017) |
| Total equity | US$ 337.33 million (2017) |
Number of employees | ~2000 |
| Website | Amphastar.com |
| Footnotes / references [1] | |
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company.[2] It was incorporated in May 2004 and primarily develops, manufactures and sells inhalation and intranasal products.[3]
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic.[4] In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.[4]
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.[5]
References
- ^ "U.S. SEC: Form 10-K, Amphstar Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. Retrieved June 27, 2018.
- ^ "Amphastar Pharmaceuticals, Inc. (AMPH)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
- ^ "Profile:Amphastar Pharmaceuticals Inc (AMPH.O)". Reuters.
- ^ a b Arsalan, Arif (February 21, 2017). "After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar's intranasal version". Endpoints.
- ^ Tyler, Eleanor (March 21, 2018). "Amphastar Patent Win Boosts Momenta, Sandoz Antitrust Case". Bloomberg. Retrieved March 24, 2018.
External links
- Official website
- Business data for Amphstar Pharmaceuticals, Inc.:
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |